Source: Postmodern Studio / Shutterstock.com
Sometimes, it’s hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ:SAVA). As the biopharmaceutical company contends with data-manipulation allegations, traders have to figure out what to do with SAVA stock. There may be evidence that the case against Cassava will be closed soon, though — and that would be bullish for Cassava Sciences.
Cassava Sciences is what I call a “ride . . .